

What We Do

Med BioGene Inc. (MBI: TSX Venture) is a life science company focused on the development and commercialization of genomic-based clinical laboratory diagnostic and screening tests for cancer and cardiovascular disease. MBI's lead products under development are LymphExpress Dx™ and LungExpress Dx™.

MBI's strategy is to partner with established diagnostics/pharmaceutical companies at an advanced stage of product development to facilitate commercialization. MBI expects to enter into its first strategic partnership for LymphExpress Dx™ in 2008 with up-front and milestone payments plus commercial royalties.

Milestones Leading To A LymphExpress Dx™ Partnership

- Establish Commercial Development Team
- Confirm high accuracy of LymphExpress Dx™
- Create with Duke University International Consortium to Develop LymphExpress Dx™
- Enter Strategic Partnership in 2008

At the
FOREFRONT of
Personalized
MEDICINE



Top Five Reasons to Buy Med BioGene Shares

1 Strong results: LymphExpress Dx™ v.1 has to date achieved a diagnostic accuracy rate of over 90%, and LungExpress Dx™ more accurately determines each patient's prognosis for survival in order to effectively guide treatment and improve the selection of patients for chemotherapy. MBI and the Ottawa Heart Institute have recently achieved promising results in respect of cardiovascular disease and we expect to publish such results in the near term.

2 Focus on Life Threatening Diseases: Lung cancer is the leading cause of cancer death in the western world and accounts for more deaths than breast cancer, prostate cancer and colon cancer combined. Lung Cancer and lymphoma are the number two and four most common cancers afflicting over 213,000 and 74,000 individuals per year in the United States alone. Cardiovascular disease is the leading cause of death in the western world, with approximately 17 million people suffering from coronary artery disease.

3 Significant Market Values: The annual market value for LymphExpress Dx™ and LungExpress Dx™ is estimated to be approximately \$1.2 billion, and the market value for cardiovascular disease diagnostics is also significant.

4 Favourable Current Market Cap: MBI's current market capitalization is under \$10 million. Based upon the market capitalization of other genomic-based diagnostic companies and the significant market values and strong scientific results achieved by MBI in each product under development, MBI is significantly undervalued.

5 World-class Collaborations with Leading Research Teams: MBI is collaborating with internationally acclaimed scientists and physicians at Duke University, Toronto's University Health Network (Princess Margaret Hospital) and the University of Ottawa Heart Institute and through collaborations MBI has access to valuable patient samples for the development and validation of product candidates. Such collaborations provide MBI with a significant competitive advantage against other commercial entities attempting to develop similar tests.

Share Capital

Common Shares	29,093,828
Stock Options	4,277,500
Warrants	7,493,508
Brokers' Warrants	517,282
Common Shares (Fully Diluted)	41,242,108



For investor relations information contact:
Peterson Capital
604.684.2883 | rick@rickpeterson.ca
www.petersoncapital.ca

The Howard Group Inc.
888.221.0915 | info@howardgroupinc.com
www.howardgroupinc.com

